Asparagus Capsule Consumption and Blood Sugar and Lipids and Oxidative Stress

Phase 2

Completed

• Conditions: Asparagus Capsule Consumption
• Interventions: Dietary Supplement: Asparagus capsule; Other: Placebo capsule

• Registration Number: NCT06195813
• Lead Sponsor: Burapha University

Brief Summary

Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.

Detailed Description

The study design was cross-sectional. Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels. Analysis of covariance was used to analyze parameters between groups and paired t-test was used to analyze parameters intra-group.

Study Timeline

• Study Start: 2022-12-20
• Primary Completion: 2023-09-14
• Study Completion: 2023-09-14
• Study First Submitted: 2023-12-21
• Status Verified: 2024-01
• Study First Submitted QC: 2024-01-05
• Study First Posted: 2024-01-08
• Last Update Submitted: 2024-01-10
• Last Update Posted: 2024-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

• Man or woman, aged between 18 to 59 years
• Body mass index more than 23 (Asian criteria)
• No history of hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer
• No regular intake of dietary supplements, i.e., vitamins, antioxidants
• No regular smokers or alcohol drinkers (>2 times per week)
• Not sportman or regular exerciser (>2 times per week or >150 min per week)
• No food allergy, especially shoot

Exclusion Criteria

• Current signs or symptoms of infection, i.e., fever, hyperpnea, dyspnea, and palpitations.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Asparagus capsule	Asparagus capsule	Participants were randomized to receive an arm. In this arm, participants received asparagus capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.
Placebo capsule	Placebo capsule	Participants were randomized to receive an arm. In this arm, participants received placebo capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.

Primary Outcome Measures

Name	Time	Method
Level of body fat	Day 0 and end of 12 weeks	Level of body fat was measured in percentage unit
Level of fat mass	Day 0 and end of 12 weeks	Level of fat mass was measured in kilogram unit
Level of fat distribution	Day 0 and end of 12 weeks	Level of fat distribution was measured by ratio of waist (centimeter) to hip (centimeter)
Concentration of blood glucose	Day 0 and end of 12 weeks	Concentration of blood glucose was measured in serum in mmol/L unit
Concentration of blood insulin	Day 0 and end of 12 weeks	Concentration of blood insulin was measured in serum in uU/mL (microunit/milliliter) unit
Concentration of blood malondialdehyde	Day 0 and end of 12 weeks	Concentration of blood malondialdehyde was measured in plasma in uM (micromolar) unit
Concentrations of blood lipids	Day 0 and end of 12 weeks	Concentrations of total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured in serum in mg/dL unit
Concentration of blood protein carbonyl	Day 0 and end of 12 weeks	Concentration of blood protein carbonyl was measured in plasma in nmol/mg protein unit

Secondary Outcome Measures

Name	Time	Method
Concentrations of blood glucose from oral glucose tolerance test	At 0 minute before glucose consumption and at 30, 60, 90, 120 minutes after glucose consumption	Concentrations of blood glucose were measured before and after glucose consumption at 75 g/100 ml in mg/dL unit

Trial Locations

Locations (1)

Faculty of Allied Health Sciences, Burapha University; 🇹🇭 Mueang, ChonBuri, Thailand